The effect of androgens on lipids

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 2, 2013, Pages 132-139

  Monroe, Anne K ^a   Dobs, Adrian S ^b  

^a Division of General Internal Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Lipids; Testosterone

Indexed keywords

ALBUMIN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; CHOLESTEROL; CHYLOMICRON; DUTASTERIDE; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE ENANTATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANDROGEN THERAPY; ARTERIAL WALL THICKNESS; CAG REPEAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; HUMAN; LIPOPROTEIN METABOLISM; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; REVIEW; RISK REDUCTION; SERTOLI CELL;

ANDROGENS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; LIPIDS; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TESTOSTERONE;

EID: 84874948080     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835edb71     Document Type: Review

References (50)

1. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol 2009; 161:435-442.
2. Khaw K, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men:European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116:2694-2701.
3. Haring R, Völzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31:1494.
4. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109-122.
5. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab 2010; 95:639-650.
6. Matsumoto AM, Bremner WJ. Testicular disorders. In Melmed SPK, Larsen PR, Kronenberg HM, editors. Williams textbook of endocrinology. Philadelphia, PA: Elsevier Saunders; 2011. pp. 688-777.
7. Braunstein GD, Testes. In Gardner DG, Shoback D, editors. Greenspan's basic and clinical endocrinology. McGraw Hill; 2011.
8. Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men. Diabetes Care 2009; 32:1049-1051.
9. Semenkovich C, Goldberg A, Goldberg I. Disorders of lipid metabolism. In Melmed SPK, Larsen PR, Kronenberg HM, editors. Williams textbook of endocrinology. 12th ed. Elsevier; 2011.
10. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012; 380:572-580.
11. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002; 296:1051-1057.
12. Schleich F, Legros J. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004; 151:415-424.
13. Wu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24:183-217.
14. Ma RCW, Tong PCY. Testosterone levels and cardiovascular disease. Heart 2010; 96:1787-1788.
15. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93:68-75.
16. Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:3007-3019.
17. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171:583-592.
18. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97:870-875.
19. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. J Am Coll Cardiol 2011; 58.
20. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94:2353-2359.
21. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96:1821-1825.
22. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96:67-72.
23. Haffner SM, Valdez RA. Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 1995; 98:S40-S47.
24. Haffner S, Mykkänen L, Valdez R, Katz M. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77:1610-1615.
25. Agledahl I, Skjærpe PA, Hansen JB, Svartberg J. Low serum testosterone in men is inversely associated with nonfasting serum triglycerides: the Tromso study. Nutr Metab Cardiovasc Dis 2008; 18:256-262.
26. Mäkinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 2008; 197:688-693.
27. Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb Vac Biol 1991; 11:489-494.
28. Van Pottelbergh I, Braeckman L, De Bacquer D, et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166:95-102.
29. Zmuda JM, Cauley JA, Kriska A, et al. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men a 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997; 146:609-617.
30. Vaidya D, Dobs A, Gapstur SM, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism 2008; 57:782-790.
31. Haring R, Baumeister SE, Völzke H, et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prevent Rehabil 2011; 18:86-96.
32. Haring R, Xanthakis V, Coviello A, et al. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int J Androl 2012; 35:775-782.
33. Firtser S, Juonala M, Magnussen CG, et al. Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012; 222:257-262.
34. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361:1152-1163.
35. Stanworth RD, Kapoor D, Channer KS, Jones TH. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clin Endocrinol (Oxf) 2011; 74:624-630.
36. Haring R, Ernst F, Schurmann C, et al. The androgen receptor CAG repeat polymorphism as a risk factor of low serum testosterone and its cardiometabolic effects in men. Int J Androl 2011; 35:511-520.
37. Makinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism. Aging Male 2011; 14:237-242.
38. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007; 30:1029-1034.
39. Vikan T, Johnsen S, Schirmer H, et al. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromsø study. Eur J Epidemiol 2009; 24:289-295.
40. Soisson V, Brailly-Tabard S, Empana JP, et al. Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men. Atherosclerosis 2012; 223:244-249.
41. Rubinow KB, Page ST. Testosterone, HDL and cardiovascular risk in men:the jury is still out. Clin Lipidol 2012; 7:363-365.
42. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34:513-554.
43. Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111:261-269.
44. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol Ser A 2005; 60:1451-1457.
45. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63:280-293.
46. Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560-2575.
47. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. J Am Med Assoc 2012; 307:931-939.
48. Rubinow KB, Vaisar T, Tang C, et al. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res 2012; 53:1376-1383.
49. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34:828-837.
50. Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301:1248-1251.